Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers

Published:2022-07-28 Issue:10 Volume:11 Page:1233-1240
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Wang Meng¹,Zhu Yifang¹,Huang Ming¹,Wang Hao²,Zhou Wenjia¹,Lu Dan²,Zhang Quanying¹

Affiliation:

1. Department of Pharmacy The Second Affiliated Hospital of Soochow University Suzhou City Jiangsu Province P.R. China

2. Suzhou Thery Pharmaceutical Co., Ltd Suzhou City Jiangsu Province P.R. China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1148

Reference38 articles.

1. Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

2. Clinical and Preclinical Characterisation Of The Metabolites Of The BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

3. Nilotinib a new FDA approved drug for the treatment of chronic myeloid leukemia;Malhotra M;Pharmacologyonline,2011

4. Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors

5. Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP